adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.
Company profile
Ticker
IVVD
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Adagio Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
1.Invivyd Security Corporation • 2.Invivyd Switzerland GmbH • 3.Invivyd Netherlands B.V. ...
IRS number
851403134
IVVD stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
22 Apr 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
8-K
Invivyd Announces CEO Transition
12 Apr 24
8-K
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
4 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Mar 24
8-K
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
22 Mar 24
S-3
Shelf registration
9 Feb 24
8-K
Index to Consolidated Financial Statements
9 Feb 24
Latest ownership filings
SC 13G
MAVERICK CAPITAL LTD
14 Feb 24
SC 13G
Deep Track Capital, LP
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Julie Green
26 Jan 24
3
Julie Green
26 Jan 24
4
Change in insider ownership
22 Jan 24
SC 13D/A
Adimab, LLC
22 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
4
Jeremy Gowler
20 Dec 23
4
David Hering
20 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 181.82 mm | 181.82 mm | 181.82 mm | 181.82 mm | 181.82 mm | 181.82 mm |
Cash burn (monthly) | (no burn) | 8.03 mm | 14.35 mm | 15.35 mm | 11.78 mm | 13.44 mm |
Cash used (since last report) | n/a | 55.20 mm | 98.69 mm | 105.55 mm | 81.03 mm | 92.44 mm |
Cash remaining | n/a | 126.63 mm | 83.13 mm | 76.27 mm | 100.80 mm | 89.38 mm |
Runway (months of cash) | n/a | 15.8 | 5.8 | 5.0 | 8.6 | 6.6 |
Institutional ownership, Q2 2023
87.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 12 |
Closed positions | 24 |
Increased positions | 13 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 58.73 bn |
Total shares | 104.65 mm |
Total puts | 700.00 |
Total calls | 5.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Adimab | 26.69 mm | $82.47 mm |
Mithril Ii | 11.24 mm | $0.00 |
FMR | 9.94 mm | $10.44 bn |
M28 Capital Management | 9.25 mm | $9.71 bn |
GOOG Alphabet Inc - Ordinary Shares | 5.68 mm | $5.96 bn |
GV 2019 | 5.68 mm | $0.00 |
Orbimed Advisors | 5.27 mm | $5.53 bn |
Polaris Venture Partners V | 4.80 mm | $14.83 mm |
683 Capital Management | 4.00 mm | $4.20 bn |
Slate Path Capital | 3.74 mm | $3.92 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Julie Green | Stock Option Common Stock | Grant | Acquire A | No | No | 4.43 | 240,000 | 1.06 mm | 240,000 |
19 Jan 24 | Adimab | Common Stock | Sell | Dispose S | No | No | 3.95 | 5,000,000 | 19.75 mm | 21,687,906 |
18 Dec 23 | Robert D. Allen III | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 400,000 | 1.44 mm | 400,000 |
18 Dec 23 | Duke William E. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 200,000 | 718.00 k | 200,000 |
News
Guggenheim Upgrades Invivyd to Buy, Announces $9 Price Target
5 Apr 24
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
5 Apr 24
Invivyd: Q4 Earnings Insights
28 Mar 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
26 Mar 24
Press releases
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
15 Apr 24
Invivyd Announces CEO Transition
12 Apr 24
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
4 Apr 24
Thinking about buying stock in Intellicheck, Vanda Pharmaceuticals, Dave Inc, Invivyd, or Dream Finders Homes?
25 Mar 24
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
22 Mar 24